| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 4.43 | 0.00 (0.00%) | 2.07 - 4.78 | 33.0 thousand (Below Avg) |
Market data as of 4:00PM 06/19/13. Quotes are delayed by at least 15 min.
| Open | -- |
|---|---|
| Previous Close | 4.43 |
| Day's Range | -- - -- |
| Market Cap | 642.8M |
| Avg Volume (10 Day) | 3.2M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.41 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Before the Bell Scans: Dynavax Technologies, Warner Chilcott, Avanir Pharma, and Actavis
PR Newswire - Wednesday 06/19/2013 9:00 AM ET
New Studies, Regulatory Submissions, and Leadership Changes - Research Report on St. Jude Medical, Teva Pharmaceutical Industries, Avanir Pharmaceuticals, Novo Nordisk, and Trius Therapeutics
PR Newswire - Monday 06/10/2013 8:00 AM ET
Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA
PR Newswire - Wednesday 06/05/2013 8:00 AM ET
Record Use of At-the-Market (ATM) Offerings Continues in 2013 with $161 Million Raised by U.S. Life Sciences Companies in First Quarter, Reports Brinson Patrick
PR Newswire - Tuesday 05/28/2013 8:00 AM ET
Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences
PR Newswire - Wednesday 05/22/2013 9:00 AM ET
| AVNR | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 137.36% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.91 | |
| LT Debt/Equity | 0.66 | |
| Earnings Yield | -- | |
| Price/Sales | 11.08 |
| Company | Last | Change |
|---|---|---|
| Ligand Pharmaceuticals Inc | 32.33 | 0.00% |
| Sagent Pharmaceuticals Inc | 19.67 | 0.00% |
| Momenta Pharmaceuticals Inc | 14.12 | 0.00% |
| Hi-Tech Pharmacal Co Inc | 33.86 | 0.00% |
| Supernus Pharmaceuticals Inc | 6.71 | 0.00% |
Data is delayed by at least 15 min.